<DOC>
	<DOCNO>NCT02744898</DOCNO>
	<brief_summary>The purpose study evaluate safety treatment carboplatin Abraxane patient population determine nature degree toxicity follow treatment . The single stage open label Phase II feasibility study design estimate proportion patient tolerate propose regimen 6 cycle two dose level reduction .</brief_summary>
	<brief_title>A Phase 2 Feasibility Study Abraxane Carboplatin Epithelial Neoplasms Uterus</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Female patient must high risk resect stage I disease ( papillary serous histology , clear cell histology carcinosarcoma ) , advanced stage ( III IV , histology ) recurrent endometrial cancer ( histology ) . Patients need measurable disease enroll follow surgery . Patients may receive prior cytotoxic chemotherapy . However , nonplatinum/nontaxane chemotherapy use radiation sensitization allow . Patients may receive prior radiation therapy ( include whole pelvic vaginal brachytherapy ) , hormonal therapy , therapy biologic agent , therapy must discontinue least 2 week prior entry study . If patient underwent surgery , chemotherapy indicate surgery either adjuvant treat residual disease , study treatment initiate within 8 week surgery . In patient receive prior radiation , least 4 week elapse since completion radiation therapy involve whole pelvis 50 % spine . If vaginal brachytherapy plan chemotherapy , do completion chemotherapy treatment . Poorly differentiated histology , uterine papillary serous carcinoma , clear cell carcinoma carcinosarcoma acceptable long predominant metastatic component epithelial ( versus sarcomatous ) . Patients may synchronous endometrial ovarian cancer primary . Patients must GOG performance status 0 , 1 , 2 Patients must least 18 year age . Patients must understand willingly sign approve informed consent , authorization permit release personal health information . Patients must adequate liver function : AST ALT ≤ 2.5 X upper limit normal ( ULN ) , bilirubin ≤ 1.5mg/dL . Patients must adequate bone marrow function : platelet ≥ 100,000 cells/mm3 ( transfusion independent , define receive platelet transfusion within 7 day prior laboratory sample ) , hemoglobin &gt; 9.0g/dl ANC ≥ 1,500 cells/mm3 . Patients must adequate renal function : creatinine &lt; 1.5 mg/dL recommend ; however , institutional norm acceptable . Patients must &lt; grade 2 preexist peripheral neuropathy ( per CTCAE ) . Other prior malignancy within 3 year , except nonmelanoma skin cancer synchronous ovarian primary . Eligibility high priority trial first line recurrent endometrial cancer ( unless patient unwilling participate trial ) . Patients concomitant medical illness serious uncontrolled infection , uncontrolled angina , opinion treat physician , make treatment prescribe study unreasonably hazardous patient . Patients pregnant breastfeeding . Patients third degree complete heart block eligible unless pacemaker place . Patients medication , alter cardiac conduction , digitalis , betablockers , calcium channel blocker , conduction abnormality cardiac dysfunction could enter discretion investigator . Patients history myocardial infarct within 6 month enrollment , New York Heart Association ( NYHA ) class II great heart failure symptom suspicious congestive heart failure eligible unless LVEF past 6 month document 50 % great . Patients LVEF ( perform reason ) less 50 % past 6 month ineligible .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>uterus</keyword>
	<keyword>gynecological</keyword>
</DOC>